Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Hemab Therapeutics Holdings FCF Yield % Related Terms
Hemab Therapeutics Holdings FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hemab Therapeutics Holdings FCF Yield % Chart
Hemab Therapeutics Holdings Annual Data
Trend
Dec24
Dec25
FCF Yield %
0.00
0.00
Hemab Therapeutics Holdings Semi-Annual Data
Dec24
Dec25
FCF Yield %
0.00
0.00
COAG vs ZLAB, SLS, IOVA: FCF Yield % Comparison
For the Biotechnology subindustry, Hemab Therapeutics Holdings's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hemab Therapeutics Holdings FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hemab Therapeutics Holdings's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Hemab Therapeutics Holdings's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hemab Therapeutics Holdings (COAG) has a FCF Yield % of -2.83 as of Aug. 04, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Hemab Therapeutics Holdings and its competitors. According to the industry distribution chart, Hemab Therapeutics Holdings ranks #406 out of 1410 companies in the Biotechnology industry, placing it in the top 28.8%.
Is Hemab Therapeutics Holdings' FCF Yield % too high?
Hemab Therapeutics Holdings' current FCF Yield % is -2.83. Based on the distribution chart, Hemab Therapeutics Holdings ranks #406 out of 1410 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Hemab Therapeutics Holdings has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Hemab Therapeutics Holdings' FCF Yield % compare to ZLAB and SLS?
According to the Biotechnology industry distribution chart, Hemab Therapeutics Holdings ranks #406 out of 1410 companies for FCF Yield %. This puts Hemab Therapeutics Holdings in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Hemab Therapeutics Holdings and its competitors. Hemab Therapeutics Holdings's current FCF Yield % is -2.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemab Therapeutics Holdings stock overvalued right now?
Hemab Therapeutics Holdings (COAG) has a current FCF Yield % of -2.83. The current FCF Yield % is -2.83. Hemab Therapeutics Holdings' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Hemab Therapeutics Holdings (COAG), the current FCF Yield % is -2.83 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
11GF Score
Get the complete analysis for COAG
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COAG has been successfully added to your 
